Cerluten
Cognitive / NeuroprotectionAlso known as: Brain peptide complex
Mechanism
An oral peptide complex derived from brain cortex tissue. It normalizes brain cell function and neurotransmitter balance. Used in Russian gerontology for cognitive health in aging populations. Part of Khavinson's philosophy that organ-specific peptides can restore function to aging tissues.
Technical detail
Peptide complex isolated from animal cerebral cortex, containing short peptides with proposed neurotrophic activity. Hypothesized mechanism: modulates gene expression in cortical neurons, normalizing production of neurotransmitters (dopamine, serotonin, acetylcholine) and neurotrophic factors (BDNF, NGF). In aged rat models, improved spatial memory (Morris water maze), increased dendritic spine density, and reduced lipofuscin accumulation in cortical neurons. Russian gerontological studies report improvements in cognitive function scores (MMSE) in elderly patients. Oral bioregulator form (Cytomax series). Functional analog of Cortexin (injectable brain peptide complex) but designed for oral administration.
Effects
## Detailed Effects — Cerluten ### Central Nervous System — Brain Bioregulation [Tier 3] - Tripeptide bioregulator (Ala-Glu-Asp) from the Khavinson series, designed to target brain cortical neurons. - Proposed mechanism: penetrates neuronal cell membranes and interacts with DNA promoter regions to normalize gene expression involved in neurotransmitter synthesis, synaptic function, and neuronal survival. - In vitro studies (Khavinson Institute): restoration of protein synthesis in aged cortical neuron cultures, normalization of neurotransmitter enzyme gene expression. - Proposed effects: improved cognitive function (memory, attention, processing speed), normalization of neurotransmitter balance (particularly serotonin and dopamine pathways), enhanced neuronal stress resistance, and geroprotective effects on brain tissue. - Animal studies: improved learning and memory in aged animals, reduced oxidative stress markers in brain tissue. ### Endocrine / Neuroendocrine [Tier 3] - May support hypothalamic-pituitary function through normalization of neuroendocrine gene expression. - Some practitioner reports of improved sleep quality (possibly through serotonin/melatonin pathway normalization). ### Longevity / Anti-Aging [Tier 3] - Part of the Khavinson geroprotective peptide program. - Proposed telomere-protective effects in neurons through modulation of telomerase activity and p53/p21 pathways. - May reduce accumulation of lipofuscin and other aging markers in brain tissue.
Practitioner Guide
## Practitioner Guide — Cerluten ### Clinical Context - Brain bioregulator peptide from the Khavinson/St. Petersburg Institute series. - Not FDA-approved. Available internationally as capsules or sublingual tablets. - Used in Russian gerontology clinics for age-related cognitive decline, as adjunct to comprehensive brain health protocols. ### Dosing Protocols (Practitioner Consensus) - **Capsules**: 1-2 capsules daily, 15-20 minutes before meals. - **Standard course**: 30 days. Repeat every 3-6 months. - **Loading protocol**: 2 capsules BID x 10 days, then 1 capsule daily x 20 days. ### Stacking with Other Bioregulators - **Pinealon** (pineal bioregulator) + Cerluten (brain bioregulator) = comprehensive CNS support — Pinealon normalizes circadian/melatonin rhythm while Cerluten targets cortical neurons. - **Endoluten** (pineal extract, more potent than Pinealon) + Cerluten = advanced neuro-longevity protocol. - **Vilon** (immune) + Cerluten = brain support + immune rejuvenation (common geriatric combination). - **Ventfort** (vascular) + Cerluten = brain health via both neural and vascular pathways. ### Comparison with Cerebrolysin - Cerluten and Cerebrolysin target similar tissues (brain) but through very different approaches: - **Cerluten**: short tripeptide bioregulator, oral/sublingual, acts at the gene expression level, gradual onset over days-weeks, maintenance-oriented. - **Cerebrolysin**: complex porcine brain peptide mixture, injectable (IM/IV), provides exogenous neurotrophic factors, faster onset, more potent acute effects. - Some practitioners use both: Cerebrolysin courses (10-20 days) for acute cognitive needs, Cerluten for ongoing maintenance between courses. ### Who Uses It - Patients 50+ with age-related cognitive decline (memory, processing speed). - As maintenance therapy between Cerebrolysin courses. - Longevity-focused patients in comprehensive bioregulator programs. - Post-stroke or post-TBI patients during recovery phase (adjunct to conventional rehab). ### Storage - Room temperature (15-25°C). Protect from moisture and light. - Shelf life: 2-3 years. ### Key Caveat - Tier 3 evidence only. No Western RCTs. - Should NOT replace evidence-based cognitive therapies (cholinesterase inhibitors for AD, stroke rehabilitation, etc.). - Use as an adjunct or for optimization.
Research Summary
## Research Summary — Cerluten ### Tier 1: Randomized Controlled Trials - No Western RCTs available for Cerluten specifically. ### Tier 2: Preclinical & Institutional Studies - Khavinson VK et al.: in vitro studies demonstrating short peptide bioregulators (including Ala-Glu-Asp) interact with DNA and modulate gene expression in target neurons. - Animal studies showing improved cognitive performance in aging models with peptide bioregulator administration. - The broader bioregulator program has published extensively on the gene-regulatory mechanism, though independent Western replication is limited. ### Tier 3: Case Reports & Practitioner Protocols - 20+ years of clinical use in Russian gerontology clinics. - Practitioner reports of improved memory, mental clarity, and processing speed, typically noticed after 2-3 weeks of use. - Commonly used in multi-bioregulator protocols combining Cerluten + Pinealon + Ventfort for comprehensive age-related decline. - Some practitioners report benefits for post-concussion syndrome recovery (maintenance phase). ### Gaps - No double-blind placebo-controlled RCTs in English-language journals. - No pharmacokinetic data. - Mechanism of DNA interaction proposed but not independently validated. - No comparative studies against established cognitive therapies. - Unclear how much of the observed benefit is from the specific peptide vs placebo effect in open-label clinical use. ### Active Trials - No registered trials on ClinicalTrials.gov. - St. Petersburg Institute continues research.